Comparison of Simoa and Ella to assess serum neurofilament-light chain in multiple sclerosis.
Fiche publication
Date publication
avril 2021
Journal
Annals of clinical and translational neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Gauthier A, Viel S, Perret M, Brocard G, Casey R, Lombard C, Laurent-Chabalier S, Debouverie M, Edan G, Vukusic S, Lebrun-Frénay C, De Sèze J, Laplaud DA, Castelnovo G, Gout O, Ruet A, Moreau T, Casez O, Clavelou P, Berger E, Zephir H, Trouillet-Assant S, Thouvenot E,
Lien Pubmed
Résumé
We compared Simoa and Ella immunoassays to assess serum neurofilament-light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both platforms. The Ella instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to Ella results. As for Simoa , serum neurofilament-light chain levels measured by Ella were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.
Référence
Ann Clin Transl Neurol. 2021 Apr 8;: